UCHL5 promotes ALK5 liquid-liquid phase separation to drive triple-negative breast cancer progression by suppressing autophagy -dependent ferroptosis
Year: 2026
Type: article
Abstract: Triple-negative breast cancer (TNBC) lacks therapeutic targets and has poor prognosis, creating a need for new molecular targets. We combined bioinformatics analysis of TNBC datasets with experimental validation. Techniques included gain- and loss-of-function studies, autophagy and ferroptosis assays, co-immunoprecipitation, and ubiquitination analysis. A ZIF-8-based nanoplatform co-loaded with UCHL5-IN-1 and 1,6-HD was developed and tested in vitro and in vivo. UCHL5 was overexpressed in TNBC and linked to poor survival. UCHL5 deubiquitinated and stabilized ALK5, promoting its liquid-liquid phase separation (LLPS). ALK5 condensates activated the ALK5–SMAD2/3–GPX4 axis, suppressing both autophagy and ferroptosis to drive tumor progression. Inhibiting UCHL5 disrupted this axis, restored autophagy–ferroptosis crosstalk, and inhibited tumor growth. The ZIF-8@1,6-HD@UCHL5-IN-1 nanoplatform targeted this pathway, induced ferroptosis, and suppressed TNBC growth safely in vivo. We identify a UCHL5–ALK5–LLPS axis that confers ferroptosis resistance in TNBC. Targeting this axis with a designed nanoplatform represents a promising dual-pathway therapeutic strategy against treatment resistance.
Source: Journal of Nanobiotechnology
Authors: Xinxing Wang, Nan Wang, Longjun Wang, Guangcheng Guo, Xin Duan, Bingjian Xue, Youyi Xiong, Jiangrui Chi, Yi Sun, Luhong Han, Shibo Zhang, Xilin Hou, Ziyan Du, Zeyuan Ma, Yuanyuan Li, Jia Li, Xingchao Fan, Mingzhi Zhang, Xiangnan Li, Lin Li
Institution: First Affiliated Hospital of Zhengzhou University
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $3,790
Award: G9001369203
OpenAlex ID: W4413449314
